血液透析结合血液灌流治疗血液透析患者肾性骨病的临床效果研究

Clinical Effect of Hemodialysis Combined with Hemoperfusion on Renal Bone Disease in Hemodialysis Patients

目的探究血液透析患者肾性骨病应用血液透析结合血液灌流治疗的效果。方法随机选择该院2021年2—9月期间就诊的肾性骨病患者40例,使用随机数表法分组,对照组(n=20)采用血液透析治疗,观察组(n=20)采用血液透析结合血液灌流治疗,将两组肾性骨病患者的疗效进行对比。结果观察组尿素氮(18.73±6.55)mmol/L、肌酐(684.85±210.25)μmol/L、β_(2)微球蛋白(23.39±5.08)mg/L、尿酸(235.80±77.86)μmol/L、无机磷测定(1.12±0.32)mmol/L均低于对照组,差异有统计学意义(t=2.831、4.114、3.469、2.692、8.479,P<0.05)。观察组治疗总有效率(100.00%)高于对照组,差异有统计学意义(χ^(2)=4.902,P=0.026)。结论血液透析结合血液灌流治疗血液透析患者肾性骨病的疗效显著,值得推广。

Objective To explore the effect of hemodialysis combined with hemoperfusion in the treatment of renal bone disease in hemodialysis patients.Methods Forty patients with renal bone disease who were treated in the hospital from February to September 2021 were randomly selected.The patients were divided into groups using the random number table method.The control group(n=20)was treated with hemodialysis,and the observation group(n=20)was treated with hemodialysis combined with hemoperfusion.The curative effects of the two groups of patients with renal bone disease were compared.Results In the observation group,blood urea nitrogen(18.73±6.55)mmol/L,creatinine(684.85±210.25)μmol/L,β_(2) microglobulin(23.39±5.08)mg/L,uric acid(235.80±77.86)μmol/L,inorganic phosphorus(1.12±0.32)mmol/L were lower than the control group,the difference was statistically significant(t=2.831,4.114,3.469,2.692,8.479,P<0.05).The total effective rate(100.00%)of the observation group was higher than that of the control group,the difference was statistically significant(χ^(2)=4.902,P=0.026).Conclusion The effect of hemodialysis combined with hemoperfusion on renal bone disease in hemodialysis patients is remarkable and worth popularizing.